Scientific ArticleAn International Expert Survey on the Indications and Practice of Radical Thoracic Reirradiation for Non-Small Cell Lung Cancer
Cited by (0)
Sources of support: This work was supported by an educational grant from the Beatson Cancer Charity and the University of Glasgow.
Disclosures: Dr Rulach has received research funding from the Beatson Cancer Charity and the University of Glasgow. Dr Ball has served on an advisory board for AstraZeneca. Dr Chua reports personal fees from AstraZeneca and PeerVoice, outside the submitted work. Dr Dahele has received research funding from Varian Medical Systems. Dr Gomez has received research funding from Boehringer-Ingelheim, Varian Medical Systems, AstraZeneca, Merck, and Bristol-Myers Squibb; personal fees from Varian Medical Systems, AstraZeneca, Merck, Bristol-Myers Squibb, US Oncology, Reflexion, WebMD, Vindico, and Medscape; and serves on an advisory board for AstraZeneca. Dr Hanna has served on an advisory board for AstraZeneca. Dr Louie has served on speaker’s bureau for Varian Medical Systems, Reflexion, and AstraZeneca. Dr Moghanaki has received funding from Varian Medical Systems. Dr Peedell has received speaker’s fees from Elekta. Dr Chalmers has received research funding from the Medical Research Council, Cancer Research UK, and AstraZeneca. All other authors have no disclosures to declare.
Data Sharing Statement: Research data are stored in an institutional repository and will be shared upon request to the corresponding author.